Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | IL2 | P60568 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165220 | 1.00 | CTH (0.39) | CTHPOLBMAPTHRH3LMNA | |
| SCHEMBL12377426 | 0.91 | CTH (0.35) | CTHPOLBMAPTHRH3LMNA | |
| SCHEMBL4761633 | 0.86 | HPGD (0.38) | MAPTLMNAHPGDSMN1; SMN2MEN1 | |
| SCHEMBL16851036 | 0.85 | CTH (0.33) | CTHLMNA | |
| SCHEMBL10147986 | 0.83 | HPGD (0.45) | MAPTLMNAHPGDSMN1; SMN2MEN1 | |
| SCHEMBL19116912 | 0.83 | HPGD (0.45) | MAPTLMNAHPGDSMN1; SMN2MEN1 | |
| SCHEMBL12020688 | 0.83 | LMNA (0.33) | LMNAHPGDMEN1MAPK10KMT2A | |
| SCHEMBL12092098 | 0.82 | LMNA (0.47) | MAPTLMNAHPGDSMN1; SMN2MEN1 | |
| SCHEMBL25237193 | 0.82 | CTH (0.38) | CTHPOLBMAPTHRH3LMNA | |
| SCHEMBL18461344 | 0.82 | SMN1; SMN2 (0.42) | MAPTLMNAHPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198978-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2015-12-01 | — | — | US | claimed |
| US-9102735-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2015-08-11 | — | — | US | claimed |
| US-20150174269-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2015-06-25 | — | — | US | claimed |
| US-20250325690-A1 | ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY | PINOTBIO, INC. (KR) | 2025-10-23 | — | — | US | disclosed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| CN-119546346-A | Conjugate of camptothecins combined with DDX5 protein and acid sensitive joint and immune conjugate using the same | 匹诺生物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240252670-A1 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Synthetic Vaccine Biosciences Co., Ltd. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-118001422-A | Dosage of immunoconjugates of antibodies with SN-38 with improved efficacy and reduced toxicity | 免疫医疗公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4331616-A1 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Tsinghua University (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023249473-A1 | ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY | 주식회사 피노바이오 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249473-A1 | ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY | 주식회사 피노바이오 | 2023-12-28 | — | — | WO | disclosed |
| US-20100015046-A1 | Camptothecin-Binding Moiety Conjugates | IMMUNOMEDICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7591994-B2 | Improved targetting | IMMUNOMEDICS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7591994-B2 | Improved targetting | IMMUNOMEDICS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7591994-B2 | Improved targetting | IMMUNOMEDICS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009100194-A2 | CAMPTOTHECIN-BINDING MOIETY CONJUGATES | IMMUNOMEDICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100194-A2 | CAMPTOTHECIN-BINDING MOIETY CONJUGATES | IMMUNOMEDICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080166363-A1 | Improved targetting | IMMUNOMEDICS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080166363-A1 | Improved targetting | IMMUNOMEDICS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080166363-A1 | Improved targetting | IMMUNOMEDICS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325690-A1 | ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY | DDX1, DDX18, DDX24 | CTH 2201/4885POLB 3863/4885MAPT 3836/4885 |
| US-20240252670-A1 | ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TLR8, TLR7, PDCD1LG2 | CTH 1988/4885POLB 2327/4885MAPT 3159/4885 |
| US-20100015046-A1 | Camptothecin-Binding Moiety Conjugates | TOP2A, DCLRE1A, CYTH3 | CTH 762/4885POLB 2229/4885MAPT 2095/4885 |
| US-20080166363-A1 | Improved targetting | CD47, CYTH3, FCGR2A | CTH 1660/4885POLB 3113/4885MAPT 1100/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | CTH 1685/4885POLB 1041/4885MAPT 2055/4885 |
| US-20150174269-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, CD44, DNPEP | CTH 1978/4885POLB 4159/4885MAPT 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.